Related Experiment Video
Updated: Nov 11, 2025

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
Published on: May 10, 2022
CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions
Kelsey Pan1, Kei Ohnuma2, Chikao Morimoto2
1Internal Medicine, University of Florida, Gainesville, USA.
Abstract:
CD26/Dipeptidyl peptidase IV (DPPIV) is a cell surface glycoprotein with numerous roles including glucose metabolism, immunomodulation, and tumorigenesis. CD26/DPPIV is well recognized in diabetes, with DPPIV inhibitors being a class of oral hypoglycemic drugs called gliptins that are commonly used to treat type two diabetes mellitus. Recent work also indicated a potential role for CD26 in infectious diseases, including COVID-19, and immune-mediated disorders such as rheumatoid arthritis, inflammatory bowel disease, and graft-versus-host disease. In cancer, CD26/DPPIV expression has been characterized in numerous tumors such as hematologic malignancies, malignant pleural mesothelioma (MPM), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), gastrointestinal stromal tumor (GIST), and prostate, lung, colorectal, and ovarian (PLCO) cancer. Hence, CD26 has been frequently studied as a tumor biomarker and therapeutic target. CD26/DPPIV-targeted therapies have been evaluated in various cancers, including the use of anti-CD26 monoclonal antibodies as anticancer treatment in selected neoplasms. This review highlights our current understanding of the role of CD26 in cancer, diabetes, immune-mediated diseases, and infectious diseases. Enhanced understanding of CD26 biology and function may lead to novel therapeutic approaches in multiple human diseases.
Insights
CD26/Dipeptidyl peptidase IV (DPPIV) is a glycoprotein involved in glucose metabolism, immunity, and cancer. Understanding CD26’s roles may unlock new treatments for diabetes, autoimmune diseases, infections, and cancer.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- CD26/Dipeptidyl peptidase IV (DPPIV) is a cell surface glycoprotein with diverse biological functions.
- It plays significant roles in glucose metabolism, immune system regulation, and the development of various diseases.
Purpose of the Study:
- To review the multifaceted roles of CD26/DPPIV in cancer, diabetes, immune-mediated disorders, and infectious diseases.
- To highlight CD26 as a potential biomarker and therapeutic target.
Main Methods:
- Literature review of studies on CD26/DPPIV.
- Analysis of CD26 expression and function in various pathological conditions.
Main Results:
- CD26/DPPIV is implicated in type 2 diabetes, with DPPIV inhibitors (gliptins) used as oral hypoglycemic agents.
- It plays a role in infectious diseases like COVID-19 and immune-mediated conditions such as rheumatoid arthritis and inflammatory bowel disease.
- CD26/DPPIV expression is observed in numerous cancers, including hematologic malignancies, mesothelioma, renal cell carcinoma, and lung cancer, making it a target for anticancer therapies.
Conclusions:
- CD26/DPPIV is a crucial molecule with implications across multiple human diseases.
- Further research into CD26 biology may pave the way for novel therapeutic strategies.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Cells and Secretions of the Pancreas
Exocrine function is carried out by acinar cells, organized into clusters known as acini. These cells contribute to digestion by releasing substantial quantities of enzyme-rich, alkaline digestive juices.
Concurrently, the dispersed clusters of endocrine cells throughout the...
Insulin: The Receptor and Signaling Pathways
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Cell Specific Gene Expression
Insulin Secretory Vesicles

